Can Baseline Urodynamic Findings Predict the Outcomes and Complications of Intravesical Injections of Onabotulinum Toxin A for Overactive Bladder?
Neurourology and Urodynamics · 2025
DOI: 10.1002/nau.70000 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurourology and Urodynamics, 2025. Verfasst von Kristina Aleksejeva und 6 weiteren Autor:innen. Beteiligte Einrichtung: Functional, Restorative and Adolescent Urology, University College Hospital, London, UK. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Urodynamics, Urinary Bladder, Overactive, Neuromuscular Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Introduction
Intravesical Onabotulinum Toxin A (Botox A) injections are an established minimally invasive therapy option for the treatment of refractory overactive bladder (OAB) symptoms in adults. We have assessed whether baseline urodynamic findings can predict self‐reported patient outcomes and posttreatment voiding difficulties.
Methods
We have conducted a retrospective review of 407 patients (median age 61 years, range 22–94 years, 286 women) who have received intravesical Botox A injections for refractory non‐neurogenic OAB symptoms between 2006 and 2018. Patient outcomes were assessed using the 5‐point PGI‐I scale and incidence of posttreatment voiding difficulties was noted. Results were correlated with the baseline urodynamic findings.
Results
Good response to Botox A injections was defined as PGI‐I scores of 1 and 2, and was seen in 272 patients overall (67%). Women were significantly more likely to have successful outcomes comparing to men ( p = 0.034) and the voiding detrusor contraction duration (DCD) was a further classifier for treatment success. Acute posttreatment voiding difficulties requiring catheterization were observed in 96 patients (24%) and were significantly more likely in those with good response.
Conclusion
Successful outcomes (based on the self‐reported PGI‐I score) were more likely in women and correlated positively with the increased duration of voiding detrusor contraction, but no other urodynamic parameters. The risk of developing de novo need to catheterize correlated with patient reported benefit, but not with any baseline urodynamic findings. We did not find pre‐existing bladder outflow obstruction, concurrent stress urinary incontinence or complex previous surgical history to adversely affect treatment success.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Functional, Restorative and Adolescent Urology, University College Hospital, London, UK.
- Urology, Royal Bournemouth Hospital, Bournemouth, Dorset, UK.
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Aleksejeva, K., Scrimgeour, G., Axell, R., Yasmin, H., Pakzad, M., Ockrim, J., & Greenwell, T. (2025). Can Baseline Urodynamic Findings Predict the Outcomes and Complications of Intravesical Injections of Onabotulinum Toxin A for Overactive Bladder?. Neurourology and Urodynamics. https://doi.org/10.1002/nau.70000
Vancouver
Aleksejeva K, Scrimgeour G, Axell R, Yasmin H, Pakzad M, Ockrim J, et al. Can Baseline Urodynamic Findings Predict the Outcomes and Complications of Intravesical Injections of Onabotulinum Toxin A for Overactive Bladder?. Neurourology and Urodynamics. 2025. doi:10.1002/nau.70000
BibTeX
@article{Aleksejeva2025,
author = {Aleksejeva, Kristina and Scrimgeour, Gemma and Axell, Richard and Yasmin, Habiba and Pakzad, Mahreen and Ockrim, Jeremy and Greenwell, Tamsin},
title = {Can Baseline Urodynamic Findings Predict the Outcomes and Complications of Intravesical Injections of Onabotulinum Toxin A for Overactive Bladder?},
journal = {Neurourology and Urodynamics},
year = {2025},
doi = {10.1002/nau.70000}
}
EUVIMED